Displaying drugs 10501 - 10525 of 14740 in total
TRIAZOLOPYRIMIDINE
Experimental
PLX51107
PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family.[A257246,A257251] PLX51107 is under investigation in clinical trial NCT04022785 (PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome).
Investigational
Matched Description: … PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family ... [A257246,A257251] PLX51107 is under investigation in clinical trial NCT04022785 (PLX51107 and Azacitidine …
OSI-930
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
Matched Description: … neck, non-small cell lung cancer and gastric cancers. ... OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial ... OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in …
MF101
MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational
Matched Description: … MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and ... MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone …
GT 389-255
Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and MAD) Phase I trials. It is expected to block fat absorption with fewer side effects than currently marketed lipase...
Investigational
Matched Description: … for the treatment of obesity which has completed single and multiple ascending dose (SAD and MAD) Phase ... Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate …
Hypothiocyanite ion
Hypothiocyanite ion is under investigation in clinical trial NCT02598999 (Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients).
Investigational
Matched Description: … Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients). ... under investigation in clinical trial NCT02598999 (Dose Escalation Study of ALX-009 in Healthy Men and …
VaxSyn
VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).
Investigational
Matched Description: … National Institute of Allergy and Infectious Diseases (NIAID). ... VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the …
Picrotoxin
A noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the gamma-aminobutyric acid-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]
Experimental
Matched Description: … A noncompetitive antagonist at GABA-A receptors and thus a convulsant. ... Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote …
Daxalipram
Experimental
N-phenyl-1H-pyrazole-3-carboxamide
Experimental
(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
Experimental
PF-04457845
PF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.
Investigational
Matched Description: … PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence. …
PF-05175157
PF-05175157 has been used in trials studying the basic science and treatment of Acne Vulgaris, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus Type 2, and Diabetes Mellitus, Type 2, among others.
Investigational
Matched Description: … PF-05175157 has been used in trials studying the basic science and treatment of Acne Vulgaris, Diabetes ... Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus Type 2, and Diabetes Mellitus, Type 2, among others …
Aleglitazar
Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated...
Investigational
Matched Description: … Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase ... glucose levels in a synergistic manner while also having limited side effects and toxicity. ... trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and …
Pranlukast
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Investigational
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Benzethidine
Experimental
Illicit
Piclamilast
Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. The structure for piclamilast was first elucidated in a 1995 European patent...
Experimental
Matched Description: … the structural functionalities of cilomilast and roflumilast. ... The structure for piclamilast was first elucidated in a 1995 European patent application and exhibits ... the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and …
Beta-D-Glucopyranose Spirohydantoin
Experimental
DAS869
Experimental
Displaying drugs 10501 - 10525 of 14740 in total